Sana Biotechnology (NASDAQ:SANA) versus Fate Therapeutics (NASDAQ:FATE) Financial Review

Fate Therapeutics (NASDAQ:FATE) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

97.5% of Fate Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 5.0% of Fate Therapeutics shares are owned by insiders. Comparatively, 31.1% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Fate Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Fate Therapeutics and Sana Biotechnology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1	10	3	0	2.14
Sana Biotechnology	0	1	3	0	2.75

Fate Therapeutics currently has a consensus price target of $6.58, indicating a potential upside of 87.03%. Sana Biotechnology has a consensus price target of $11.67, indicating a potential upside of 45.47%. Given Fate Therapeutics’ higher probable upside, equities analysts plainly believe Fate Therapeutics is more favorable than Sana Biotechnology.

Earnings & Valuation

This table compares Fate Therapeutics and Sana Biotechnology’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$63.53 million	6.31	-$160.93 million	($1.92)	-1.83
Sana Biotechnology	N/A	N/A	-$283.26 million	($1.53)	-5.24

Fate Therapeutics has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fate Therapeutics and Sana Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-2,933.79%	-46.49%	-34.48%
Sana Biotechnology	N/A	-88.13%	-47.16%

Summary

Fate Therapeutics beats Sana Biotechnology on 8 of the 12 factors compared between the two stocks.

About Fate Therapeutics

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

About Sana Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.